Insight Molecular Diagnostics sees 'light at end of tunnel' for FDA approval as Medicare ups ...

Insight Molecular Diagnostics is advancing toward FDA approval for its GraftAssureDx kidney transplant test aiming for late 2026, while new Medicare guidelines have increased kidney transplant test frequency, expanding the market potential significantly.

This Wire brief sits within Fusion42's coverage of Diagnostics.